Pharmaceutical manufacturers often present the kinds of specialty drugs that cost more than $10,000 per patient per year, or even more than $100,000 per patient per year, as life-saving miracle cures.
Health insurers and employer plan sponsors tend to refer to the drugs as a budget-busting menace.
Patient advocacy groups are looking at the drugs as a policy puzzle to be solved. They are trying to use the Affordable Care Act, state laws and regulations, and policymakers’ and health plan managers’ instinctive desire to help the patients to maximize the number of patients with access to the drugs.
(Related: Prescription Drug Pricing 101)
Carl Schmid , executive director of the AIDS Institute, presented his perspective on specialty drug access rules recently in Newport Beach, California, at the summer meeting of the National Council of Insurance Legislators’ Health Insurance & Long Term Care Issues Committee.
Schmid told attendeees that getting a patient’s monthly out-of-pocket cost for a drug below $75 makes the odds a patient will be able to use the drug dramatically higher than if the monthly cost is over $250 per month, according to a presentation slidedeck.
Here are three other ideas Schmid offered for making specialty drugs accessible, drawn from the slidedeck.
1. Simply limit what the patients have to pay for drugs out of pocket.
Schmid noted that New York state prohibits plans from setting higher cost-sharing amounts for non-preferred brands than for preferred brands.
He said that states such as California and Louisiana set caps on prescription co-payments.
California limits drug co-payments to $250 after the deductible is met.
Louisiana sets the limit at $150 after the deductible is met.